Camp4 Therapeutics Corporation
CAMP
$5.31
$0.030.57%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 350.00K | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | 350.00K | |
| Cost of Revenue | 9.70M | 9.56M | 9.56M | 9.82M | |
| Gross Profit | -9.70M | -9.56M | -9.56M | -9.47M | |
| SG&A Expenses | 3.81M | 3.20M | 3.20M | 2.87M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 13.52M | 12.77M | 12.77M | 12.69M | |
| Operating Income | -13.52M | -12.77M | -12.77M | -12.34M | |
| Income Before Tax | -13.48M | -12.51M | -12.51M | -11.70M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -13.48M | -12.51M | -12.51M | -11.70M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -13.48M | -12.51M | -12.51M | -11.70M | |
| EBIT | -13.52M | -12.77M | -12.77M | -12.34M | |
| EBITDA | -13.10M | -12.34M | -12.34M | -11.91M | |
| EPS Basic | -24.19 | -26.28 | -26.28 | -29.21 | |
| Normalized Basic EPS | -15.12 | -16.43 | -16.43 | -18.26 | |
| EPS Diluted | -24.19 | -26.28 | -26.28 | -29.21 | |
| Normalized Diluted EPS | -15.12 | -16.43 | -16.43 | -18.26 | |
| Average Basic Shares Outstanding | 557.40K | 476.20K | 476.20K | 400.40K | |
| Average Diluted Shares Outstanding | 557.40K | 476.20K | 476.20K | 400.40K | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |
